Inactive Instrument

Press Releases Idogen AB (publ)

Equities

IDOGEN

SE0014428561

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bids for Idogen's technology platform to be submitted no later than July 31[st]	23-07-13	AQ
Idogen's Board of Directors proposes that liquidation is not to be resolved at the Annual General Meeting on June 8.	23-06-06	AQ
Idogen working for a sale of its proprietary technology platform	23-05-30	AQ
Idogen - Q1 2023 – In a tough situation	23-05-10	AQ
Idogen in discussions about a reversed merger. The company intends to add an agenda item at the annual general meeting on June 8 for possible liquidation	23-04-28	AQ
Idogen is investigating reverse acquisitions to avoid risk of liquidation	23-04-18	AQ
Idogen Q4 2022 - The future is contingent on funding	23-02-27	AQ
Idogen publishes interim report for 1 January - 31 December 2022	23-02-24	AQ
BioStock: Idogen one of ten companies selected for field-leading event	23-02-07	AQ
Idogen invited by GJCF to participate in their 3[rd] Summit for NMOSD Tolerization	23-01-31	AQ
Idogen announces outcome of rights issue	23-01-17	AQ
Last day for subscription of shares in Idogen's rights issue is Friday January 13, 2023	23-01-09	AQ
Idogen's first clinical trial, "Toler8", briefly described in Blood	22-12-12	AQ
Idogen : Interim report Q3 2022	22-11-25	PU
BioStock: Idogen strengthens the Board with Jan Holgersson	22-11-25	AQ
Idogen's financial contribution from Horizon 2020 now finalizes with a publication	22-11-14	AQ
Idogen carries out a rights issue of approximately SEK 43.7 million	22-11-08	AQ
Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors	22-11-01	AQ
EU to disburse the remaining MSEK 4.7 of the Horizon grant	22-10-17	AQ
Idogen sharpens focus on its IDO 8 program and lowers operating expenditure	22-10-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Idogen AB (publ)

Equities

IDOGEN

SE0014428561

Press Releases

Filters